Identification of tyrosinase-related protein 2 as a tumor rejection antigen for the B16 melanoma - PubMed (original) (raw)
Identification of tyrosinase-related protein 2 as a tumor rejection antigen for the B16 melanoma
M B Bloom et al. J Exp Med. 1997.
Abstract
Recently, major advances have been made in the identification of antigens from human melanoma which are recognized by T cells. In spite of this, little is known about the optimal ways to use these antigens to treat patients with cancer. Progress in this area is likely to require accurate preclinical animal models, but the availability of such models has lagged behind developments in human tumor immunology. Whereas many of the identified human melanoma antigens are normal tissue differentiation proteins, analogous murine tumor antigens have not yet been identified. In this paper we identify a normal tissue differentiation antigen, tyrosinase-related protein 2 (TRP-2), expressed by the murine B16 melanoma which was found by screening a cDNA library from B16 with tumor-reactive cytotoxic T lymphocytes (CTL). A peptide conforming to the predicted MHC class I H2-Kb binding motif, TRP-2181-188, was identified as the major reactive epitope within TRP-2 recognized by these anti-B16 CTLs. By site-directed mutagenesis, it was shown that alteration of this epitope eliminated recognition of TRP-2. It was further demonstrated that a CTL line raised from splenocytes by repeated stimulation in vitro with this peptide could recognize B16 tumor and was therapeutic against 3-d-old established pulmonary metastases. The use of TRP-2 in a preclinical model of tumor immunotherapy may be helpful in suggesting optimal vaccination strategies for cancer therapy in patients.
Figures
Figure 1
Stimulation of mINF-γ release from line A T cells by various murine tumor lines. 105 line A T cells and 105 tumor cells were coincubated in 2 ml of CM for 24 h. Aliquots of supernatant were assayed for mINF-γ. All targets were MHC type H2b except P815, 9873, and CT26 (H2d). Line A CTLs demonstrated relative specificity for the B16 tumor.
Figure 2
Alignment of TRP-2 inserts found by cDNA expression library screening with anti-B16 CTLs. The top line indicates the composite TRP-2 cDNA sequence described by Jackson et al. (8). The next line (shaded) represents the coding region for the TRP-2 protein. The location of the five TRP-2 cDNA clones identified are shown below (striped).
Figure 3
Release of mIFN-γ by line A when incubated with MC-38 (H2b) and varying amounts of TRP-2181–188 peptide (circles). No significant mIFN-γ release was seen when MC-38 was incubated with peptide without line A (square) or with line A without peptide (triangle).
Figure 4
Treatment of 3-d-old pulmonary metastases from B16 by the intravenous administration of T cells reactive with TRP-2181–188 generated by in vitro peptide stimulation of splenocytes from normal or B16immunized mice. Low-dose systemic IL-2 was given with adoptive cell transfer. Therapeutic effects were seen from anti–TRP-2181–188 CTLs from normal mice (P = 0.0004 vs. IL-2 alone, and P = 0.014 vs. ovalbumin257–264 stimulated cultures), as well as from anti-B16 immunized mice (P = 0.0003 vs. IL-2 alone, and P = 0.010 vs. ovalbumin257–264 stimulated cultures).
Similar articles
- Relevance of the tumor antigen in the validation of three vaccination strategies for melanoma.
Bellone M, Cantarella D, Castiglioni P, Crosti MC, Ronchetti A, Moro M, Garancini MP, Casorati G, Dellabona P. Bellone M, et al. J Immunol. 2000 Sep 1;165(5):2651-6. doi: 10.4049/jimmunol.165.5.2651. J Immunol. 2000. PMID: 10946294 - Dendritic cells break tolerance and induce protective immunity against a melanocyte differentiation antigen in an autologous melanoma model.
Schreurs MW, Eggert AA, de Boer AJ, Vissers JL, van Hall T, Offringa R, Figdor CG, Adema GJ. Schreurs MW, et al. Cancer Res. 2000 Dec 15;60(24):6995-7001. Cancer Res. 2000. PMID: 11156402 - Dendritic cell-based genetic immunization in mice with a recombinant adenovirus encoding murine TRP2 induces effective anti-melanoma immunity.
Tüting T, Steitz J, Brück J, Gambotto A, Steinbrink K, DeLeo AB, Robbins P, Knop J, Enk AH. Tüting T, et al. J Gene Med. 1999 Nov-Dec;1(6):400-6. doi: 10.1002/(SICI)1521-2254(199911/12)1:6<400::AID-JGM68>3.0.CO;2-D. J Gene Med. 1999. PMID: 10753065 - New tumor antigens recognized by T cells.
Van den Eynde B, Brichard VG. Van den Eynde B, et al. Curr Opin Immunol. 1995 Oct;7(5):674-81. doi: 10.1016/0952-7915(95)80076-x. Curr Opin Immunol. 1995. PMID: 8573311 Review.
Cited by
- A Paradoxical Tumor Antigen Specific Response in the Liver.
Trehan R, Zhu XB, Huang P, Wang X, Soliman M, Strepay D, Nur A, Kedei N, Arhin M, Ghabra S, Rodríguez-Matos F, Benmebarek MR, Ma C, Korangy F, Greten TF. Trehan R, et al. bioRxiv [Preprint]. 2024 Sep 24:2024.09.19.614002. doi: 10.1101/2024.09.19.614002. bioRxiv. 2024. PMID: 39372792 Free PMC article. Preprint. - IMMUNE AND MOLECULAR CORRELATES OF RESPONSE TO IMMUNOTHERAPY REVEALED BY BRAIN-METASTATIC MELANOMA MODELS.
Daugherty-Lopès A, Pérez-Guijarro E, Gopalan V, Rappaport J, Chen Q, Huang A, Lam KC, Chin S, Ebersole J, Wu E, Needle GA, Church I, Kyriakopoulos G, Xie S, Zhao Y, Gruen C, Sassano A, Araya RE, Thorkelsson A, Smith C, Lee MP, Hannenhalli S, Day CP, Merlino G, Goldszmid RS. Daugherty-Lopès A, et al. bioRxiv [Preprint]. 2024 Oct 9:2024.08.26.609785. doi: 10.1101/2024.08.26.609785. bioRxiv. 2024. PMID: 39372744 Free PMC article. Preprint. - TRP-2 / gp100 DNA vaccine and PD-1 checkpoint blockade combination for the treatment of intracranial tumors.
Pearson JRD, Puig-Saenz C, Thomas JE, Hardowar LD, Ahmad M, Wainwright LC, McVicar AM, Brentville VA, Tinsley CJ, Pockley AG, Durrant LG, McArdle SEB. Pearson JRD, et al. Cancer Immunol Immunother. 2024 Jul 2;73(9):178. doi: 10.1007/s00262-024-03770-x. Cancer Immunol Immunother. 2024. PMID: 38954031 Free PMC article. - Design and Evaluation of Synthetic Delivery Formulations for Peptide-Based Cancer Vaccines.
Song K, Pun SH. Song K, et al. BME Front. 2024 Mar 21;5:0038. doi: 10.34133/bmef.0038. eCollection 2024. BME Front. 2024. PMID: 38515636 Free PMC article. - Structural and Dynamic-Based Characterization of the Recognition Patterns of E7 and TRP-2 Epitopes by MHC Class I Receptors through Computational Approaches.
Balasco N, Tagliamonte M, Buonaguro L, Vitagliano L, Paladino A. Balasco N, et al. Int J Mol Sci. 2024 Jan 23;25(3):1384. doi: 10.3390/ijms25031384. Int J Mol Sci. 2024. PMID: 38338663 Free PMC article.
References
- Rosenberg SA, Yannelli JR, Yang JC, Topalian SL, Schwartzentruber DJ, Weber JS, Parkinson DR, Seipp CA, Einhorn JH, White DE. Treatment of patients with metastatic melanoma with autologous tumorinfiltrating lymphocytes and interleukin 2. J Natl Cancer Inst. 1994;86:1159–1166. - PubMed
- Robbins PF, El-Gamil M, Kawakami Y, Stevens E, Yannelli JR, Rosenberg SA. Recognition of tyrosinase by tumor-infiltrating lymphocytes from a patient responding to immunotherapy (erratum published 54:3952) Cancer Res. 1994;54:3124–3126. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Molecular Biology Databases
Research Materials